Aided by malarone and cutivate generic, the US business of Glenmark Pharma saw recovery in the fourth quarter of FY12. In an interview with CNBC-TV18, Glenn Saldanha, MD & CEO of Glenmark said, the company expects its domestic market to outperform industry in FY13.
first published: May 9, 2012 11:42 am
A collection of the most-viewed Moneycontrol videos.
Point-to-Point vs Rolling Returns for Mutual Funds: Full Breakdown
From Hesitant Heir to Undisputed Leader: Sanjiv Bajaj's Leadership Story
Nifty Fails To Defend 26,000 Amid Sluggish Start To Final Week Of 2025| Closing Bell Live
Nifty Aims To Defend 26,000 Amid Thin Volumes, Record-Low VIX| Opening Bell Live
